RxDoctor Payments Data

Naveed Sami, MD

Dermatology · Orlando, FLNPI 1255412102

Payments from drug & device makers

$35,597in general payments, 2019–2025

Across 18 payments — averaging $1977.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$18K
  • E.r. Squibb & Sons, L.L.C.$16K
  • Argenx US, Inc.$1K
  • Regeneron Healthcare Solutions, Inc.$234
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$90
  • Pfizer$71
  • plus $32 from 1 others

What the payments were for

  • Travel & lodging$35832%
  • Food & beverage$60954%
  • Education$16014%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,597 in reported general payments places this provider in the 85th percentile of 1,147 dermatology providers in Florida.

See all dermatology providers in Florida

Medicare billing

Part B allowed, 2024
$217,406
Medicare patients
395
Services billed
4,000

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa11$230,785
Cosentyx Sensoready (2 Pens)Secukinumab20$162,530
Dupixent SyringeDupilumab25$94,173
Dupixent PenDupilumab25$92,605
JubliaEfinaconazole17$18,931
Tacrolimus50$6,167
Fluorouracil77$5,665
Pimecrolimus12$3,747
Ketoconazole168$2,590
Triamcinolone Acetonide132$2,518
Mycophenolate Mofetil30$2,507
Hydrocortisone102$1,315
Clindamycin Phosphate26$1,308
Fluocinolone Acetonide22$1,027
Mycophenolic AcidMycophenolate Sodium14$994

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$90$18,93117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,147 dermatology providers in Florida.

Other dermatology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →